ArticleClinics (Sao Paulo, Brazil)2026
Association between urinary polycyclic aromatic hydrocarbon metabolites and diabetes-related mortality: a longitudinal study in U.S. adults.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to explore the association between urinary Polycyclic Aromatic Hydrocarbons (PAHs) and diabetes prevalence and all-cause mortality in U.S. adults using data from 8,124 participants in the 2003-2014 NHANES cycles
methodsWeighted logistic regression and Cox proportional hazards models were employed to analyze the effects of individual and combined PAH metabolites. Confounders were adjusted, and nonlinear relationships were explored through restricted cubic splines.
resultsWeighted quantile sum regression revealed that co-exposure to six urinary PAHs was significantly associated with higher diabetes prevalence (OR = 1.131, 95% CI 1.008-1.269) and all-cause mortality (OR = 1.330, 95% CI 1.051-1.684), with 2-hydroxynaphthalene contributing most to diabetes risk and 1-hydroxynaphthalene to mortality risk within the mixture. In exploratory analyses of individual metabolites, nominal (unadjusted for multiple comparisons) positive associations were observed for ΣPAHs and 1-hydroxynaphthalene with diabetes prevalence. ΣPAHs also showed a modest association with all-cause mortality.
conclusionsThese findings suggest that PAH exposure is associated with a higher prevalence of diabetes and, among individuals with diabetes, higher all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.